1.27
price down icon3.05%   -0.04
after-market Handel nachbörslich: 1.34 0.07 +5.51%
loading
Schlusskurs vom Vortag:
$1.31
Offen:
$1.3
24-Stunden-Volumen:
19,644
Relative Volume:
0.15
Marktkapitalisierung:
$3.89M
Einnahmen:
$129.20K
Nettoeinkommen (Verlust:
$-7.44M
KGV:
-0.1135
EPS:
-11.19
Netto-Cashflow:
$-8.62M
1W Leistung:
-3.05%
1M Leistung:
-15.89%
6M Leistung:
-75.36%
1J Leistung:
-91.89%
1-Tages-Spanne:
Value
$1.24
$1.305
1-Wochen-Bereich:
Value
$1.22
$1.35
52-Wochen-Spanne:
Value
$1.22
$16.80

Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile

Name
Firmenname
Sonnet Biotherapeutics Holdings Inc
Name
Telefon
609-375-2227
Name
Adresse
100 OVERLOOK CENTER, PRINCETON, NJ
Name
Mitarbeiter
0
Name
Twitter
@SonnetBio
Name
Nächster Verdiensttermin
2024-08-12
Name
Neueste SEC-Einreichungen
Name
SONN's Discussions on Twitter

Vergleichen Sie SONN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SONN
Sonnet Biotherapeutics Holdings Inc
1.27 3.89M 129.20K -7.44M -8.62M -11.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Sonnet Biotherapeutics Holdings Inc Aktie (SONN) Neueste Nachrichten

pulisher
Apr 01, 2025

Sonnet Announces Release of Corporate Update Video - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - dailyvoice.com

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Leadership Change at Sonnet BioTherapeutics: Founder Passes, New Executive Team Steps In - Stock Titan

Apr 01, 2025
pulisher
Mar 30, 2025

Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia

Mar 28, 2025
pulisher
Mar 27, 2025

Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire

Mar 27, 2025
pulisher
Mar 26, 2025

Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 21, 2025

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Major Patent Win: Sonnet's Revolutionary IL-18 Cancer Treatment Shows Superior Binding Properties - StockTitan

Mar 19, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

XRP Plunges as Recession Panic and Crypto Summit Fallout Slam Investors - The Globe and Mail

Mar 11, 2025
pulisher
Mar 07, 2025

Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025
pulisher
Mar 04, 2025

SONN stock touches 52-week low at $1.33 amid market challenges - Investing.com UK

Mar 04, 2025
pulisher
Feb 27, 2025

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan

Feb 26, 2025
pulisher
Feb 21, 2025

Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - The AM Reporter

Feb 21, 2025
pulisher
Feb 20, 2025

Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com Australia

Feb 20, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics advances novel ADC platform - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks

Feb 19, 2025
pulisher
Feb 19, 2025

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New ADC Platform Challenge Established Cancer Drugs? Preclinical Data Shows Promise - StockTitan

Feb 19, 2025
pulisher
Feb 18, 2025

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Sonnet BioTherapeutics Announces Acceptance of Poster Presentation at 2025 AACR IO Conference - Nasdaq

Feb 18, 2025
pulisher
Feb 18, 2025

Revolutionary Cancer Treatment Breakthrough: Sonnet's IL-12 Protein Research Heads to AACR 2025 - StockTitan

Feb 18, 2025
pulisher
Feb 16, 2025

Sonnet BioTherapeutics appoints new chief business officer - MSN

Feb 16, 2025

Finanzdaten der Sonnet Biotherapeutics Holdings Inc-Aktie (SONN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):